Correspondence

Prion-induced neuronal injury in vivo is associated with prostaglandin E2 production, a process that can be reproduced in tissue-culture models of prion disease. In the present study, neuronal phospholipase A2 was activated by glycosylphosphatidylinositols (GPIs) isolated from the cellular prion protein (PrPc) or from disease-associated isoforms (PrPSc), resulting in prostaglandin E2 production, but not by GPIs isolated from Thy-1. The ability of GPIs to activate neuronal phospholipase A2 was lost following the removal of acyl chains or cleavage of the phosphatidylinositol–glycan linkage, and was inhibited by a mAb that recognized phosphatidylinositol. In competition assays, pretreatment of neurons with partial GPIs, inositol monophosphate or sialic acid reduced the production of prostaglandin E2 in response to a synthetic miniprion (sPrP106), a synthetic correlate of a PrPSc species found in Gerstmann–Sträussler–Scheinker disease (HuPrP82–146), prion preparations or high concentrations of PrP-GPIs. In addition, neurons treated with inositol monophosphate or sialic acid were resistant to the otherwise toxic effects of sPrP106, HuPrP82–146 or prion preparations. This protective effect was selective, as inositol monophosphate- or sialic acid-treated neurons remained susceptible to the toxicity of arachidonic acid or platelet-activating factor. Addition of PrP-GPIs to cortical neuronal cultures increased caspase-3 activity, a marker of apoptosis that is elevated in prion diseases. In contrast, treatment of such cultures with inositol monophosphate or sialic acid greatly reduced sPrP106-induced caspase-3 activity and, in co-cultures, reduced the killing of sPrP106-treated neurons by microglia. These results implicate phospholipase A2 activation by PrP-GPIs as an early event in prion-induced neurodegeneration